APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Slides:



Advertisements
Similar presentations
Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Advertisements

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.
High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules  Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
SC17.02 Lung Cancer in China: Challenges and Perspectives
ALK FISH and IHC: You Cannot Have One without the Other
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD 
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.
A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.
Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.
Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations  Benjamin Haaland, PhD, Pui San Tan,
An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.
George Blumenschein, MD, John V. Heymach, MD, PhD 
Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors  Benny Weksler, MD, Anthony Holden, MD, Jennifer.
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 
Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD 
Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.
In This Issue Journal of Thoracic Oncology
Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E
PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?  Steven G. Gray, PhD  Journal of Thoracic.
Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q
PUB010 Intraoperative Blood Loss is an Independent Predictor of Poor Disease Free Survival for Patients Undergoing VATS Lobectomy for Lung Cancer  M.
Onkar V. Khullar, MD, Yuan Liu, PhD, Theresa Gillespie, PhD, Kristin A
Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS 
Heidi B. Rolke, Frode Gallefoss  Journal of Thoracic Oncology 
Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)  Gregory A. Otterson,
Mitotic Inhibitors Journal of Thoracic Oncology
PD5-1-7: Time trends in nodal CT volume and nodal motion during radiotherapy for patients with stage III non-small cell lung cancer  Geert Bosmans, Angela.
P3-252: Limited surgery for elderly patients with non-small cell lung cancer who have high risk for lobectomy: Comparison of the short- and the long-term.
P3-255: Tumor size as a prognostic factor for the survival of surgically treated stage Ia non-small cell carcinoma  Gustavo A. Lyons, Silvia Quadrelli,
Mirror Mirror on the Wall, Who Is the Fairest of Them All
ES Lung Cancer Surgery for High Risk Patients
MTP13-01: Indications and limitations of bronchoscopy
Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011)  Ellen.
It’s All in the “Swerve of the Curve”
A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.
M. Kusumoto  Journal of Thoracic Oncology 
Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View  Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,
Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base  Susan E. Combs, MA, Jacquelyn.
Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M
Jie Huang, Juan Peng, Linlang Guo, MD, PhD 
In This Issue Journal of Thoracic Oncology
Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J
MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a.
Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J
International Thymic Malignancies Interest Group: A Way Forward
European Lung Cancer Conference (ELCC) 2016 Organisation
Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer  Eun Young Kim, MD, Young Saing Kim, MD, Inkeun Park, MD,
Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer  Jin Gu Lee, MD, Chang Young.
IASLC 6th Latin American Conference on Lung Cancer
OA Survival Trends Among Non-Small Cell Lung Cancer (NSCLC) Patients Over A Decade: Impact of Initial Therapy at Academic Centers  B. Dholaria,
Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M
Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer  James B. Yu, MD, Roy H. Decker, MD, PhD,
Sleeve Lobectomy as an Alternative Procedure to Pneumonectomy for Non-small Cell Lung Cancer  Joon Suk Park, MD, Hee Chul Yang, MD, Hong Kwan Kim, MD,
Mark A. Socinski, MD  Journal of Thoracic Oncology 
Presentation transcript:

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28   Journal of Thoracic Oncology  Volume 7, Issue 11, Pages S483-S504 (November 2012) DOI: 10.1097/01.JTO.0000423889.14152.06 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Overall survival Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10.1097/01.JTO.0000423889.14152.06) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Progression free survival Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10.1097/01.JTO.0000423889.14152.06) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10.1097/01.JTO.0000423889.14152.06) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Overall survival curves of 738 NSCLC patients who were performed VATS lobectomy. Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10.1097/01.JTO.0000423889.14152.06) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Procedure of CT-TBB Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10.1097/01.JTO.0000423889.14152.06) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2012 7, S483-S504DOI: (10. 1097/01. JTO Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.